` ZYME (Zymeworks Inc) vs S&P 500 Comparison - Alpha Spread

ZYME
vs
S&P 500

Over the past 12 months, ZYME has significantly outperformed S&P 500, delivering a return of 50% compared to the S&P 500's 9% growth.

Stocks Performance
ZYME vs S&P 500

Loading
ZYME
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
ZYME vs S&P 500

Loading
ZYME
S&P 500
Difference
www.alphaspread.com

Performance By Year
ZYME vs S&P 500

Loading
ZYME
S&P 500
Add Stock

Competitors Performance
Zymeworks Inc vs Peers

S&P 500
ZYME
ABBV
AMGN
GILD
VRTX
Add Stock

Zymeworks Inc
Glance View

Market Cap
884.1m USD
Industry
Biotechnology

Zymeworks Inc. is a biopharmaceutical company. The company is headquartered in Middletown, Delaware and currently employs 286 full-time employees. The company went IPO on 2019-06-24. Its lead product candidate is zanidatamab, a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Its product candidate ZW49, combines the design of zanidatamab with its ZymeLink ADC platform, comprised of its cytotoxin and cleavable linker. The firm operates through a number of platforms, including Azymetric, ZymeLink, EFECT and ProTECT. Its Azymetric is a bispecific platform that enables therapeutic antibodies to simultaneously bind multiple distinct locations on a target or to multiple targets. The Company’s ZymeLink is an antibody-drug conjugate (ADC) platform comprised of cytotoxins and the linker technology used to couple these cytotoxins to tumor-targeting antibodies or proteins.

ZYME Intrinsic Value
14.42 USD
Undervaluation 12%
Intrinsic Value
Price
Back to Top